ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.

Anhui Anke Biotechnology (Group) Co., Ltd.

300009

CNE100000GY2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
9.79 ^CNY	-3.07%		-2.78%	-4.21%

25/04	Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
28/03	Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023	CI

Anhui Anke Biotechnology Co., Ltd. Announces Cash Dividend for the Year 2021, Payable on 13 May 2022

May 11, 2022 at 01:03 am IST

Anhui Anke Biotechnology (Group) Co., Ltd. announced plan to be implemented of Cash dividend/10 shares CNY 2.00083400 (tax included) A shares for the year 2021. Record date on 12 May 2022, Ex-date on 13 May 2022 and Payment date on 13 May 2022.

Latest news about Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023	28/03	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Anke Biotechnology's Unit Passes US FDA Workplace Inspection	19/02	MT
Anhui Anke Biotechnology Co., Ltd. agreed to acquire 11.31% stake in Anhui Xinhuakun Biological Engineering Co., Ltd. from a group of shareholders for CNY 10.3 million.	13/12	CI
Anhui Anke Biotechnology Gets Nod to Market Breast Cancer Drug	01/11	MT
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/23/24	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Anhui Anke Biotechnology Co., Ltd. Declares Final Cash Dividend for 2022 on A Shares, Payable on 19 May 2023	16/23/16	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Anhui Anke Biotechnology Co., Ltd. Approves Cash Dividend for 2022	22/23/22	CI
Anhui Anke Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year of 2022	28/23/28	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Anhui Anke Biotechnology Co., Ltd. Announces Board Elections	27/22/27	CI
Anhui Anke Biotechnology Unit Gets Regulatory Nod For Anti-Postpartum Hemorrhage Drug	23/22/23	MT
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	08/22/08	CI
Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback announced on February 8, 2022, has expired with 4,187,406 shares, representing 0.26% for CNY 40.05 million.	07/22/07	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	04/22/04	CI
Anhui Anke Biotech to Form mRNA Vaccine JV With Startup	18/22/18	MT
Anhui Anke Biotechnology Co., Ltd. Announces Cash Dividend for the Year 2021, Payable on 13 May 2022	11/22/11	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Anhui Anke Biotechnology Co., Ltd. Approves Profit Distribution	22/22/22	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	06/22/06	CI

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

Duration

Period

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

More charts

Company Profile

Anhui Anke Biotechnology (Group) Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of biological products, Chinese patent drugs, chemical synthetic drugs, peptide drugs and nucleic acid detection products. The Companyâs main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Anhui Anke Biotechnology (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.79 CNY

Average target price

19.54 CNY

Spread / Average Target

+99.59%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.	-4.21%	2.33B
CSL LIMITED	-2.00%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.73%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.52B
INCYTE CORPORATION	-8.50%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals

Anhui Anke Biotechnology (Group) Co., Ltd.

Equities

300009

CNE100000GY2

Pharmaceuticals

Anhui Anke Biotechnology Co., Ltd. Announces Cash Dividend for the Year 2021, Payable on 13 May 2022

Latest news about Anhui Anke Biotechnology (Group) Co., Ltd.

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Anhui Anke Biotechnology (Group) Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals